The present disclosure provides a compound of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.

Benzylamino-oxoethyl benzamide compounds for use in treating diseases and conditions associated with abnormal cell function related to endoplasmic reticulum (ER) stress. For example, the compounds can be used as suppressors of ER stress-induced pancreatic -cell dysfunction and death, for example in the treatment of Type 1 and Type 2 diabetes. The compounds can also be used in treatments for chronic heart disease, neurodegenerative diseases, retinal degeneration, and other metabolic disorders associated with ER stress.

Benzylamino-oxoethyl benzamide compounds for use in treating diseases and conditions associated with abnormal cell function related to endoplasmic reticulum (ER) stress. For example, the compounds can be used as suppressors of ER stress-induced pancreatic -cell dysfunction and death, for example in the treatment of Type 1 and Type 2 diabetes. The compounds can also be used in treatments for chronic heart disease, neurodegenerative diseases, retinal degeneration, and other metabolic disorders associated with ER stress.

The present invention is directed to benzamide-containing compounds of formula I

##STR00001##

or pharmaceutically acceptable salts thereof which inhibit the P2X.sub.7 receptor, and their use in the treatment of depression.

The present invention is directed to benzamide-containing compounds of formula I

##STR00001##

or pharmaceutically acceptable salts thereof which inhibit the P2X.sub.7 receptor, and their use in the treatment of depression.

Provided herein are compounds and compositions useful in increasing PPAR activity. The compounds and compositions provided herein are useful for the treatment of PPAR related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Provided herein are compounds and compositions useful in increasing PPAR activity. The compounds and compositions provided herein are useful for the treatment of PPAR related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

The present invention discloses anti-malarial compound of formula (I) Formula (I) wherein, X is selected from O or NH; R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 is selected from H or OMe or CH.sub.3, CH.sub.2OCH.sub.2 or CHCHCHCH; Y is selected from O or NH and R.sub.6, R.sub.7 is selected from the following compounds: or pharmaceutically acceptable salts thereof, process for preparation and a pharmaceutical composition containing the same. ##STR00001##

The present invention discloses anti-malarial compound of formula (I) Formula (I) wherein, X is selected from O or NH; R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 is selected from H or OMe or CH.sub.3, CH.sub.2OCH.sub.2 or CHCHCHCH; Y is selected from O or NH and R.sub.6, R.sub.7 is selected from the following compounds: or pharmaceutically acceptable salts thereof, process for preparation and a pharmaceutical composition containing the same. ##STR00001##